Concepedia

Alison Skrinar

AS

34

Publications

4K

Citations

25

H-Index

2003

Active since

Affiliations

Ultragenyx Pharmaceutical (United States)(Current)

Indiana University – Purdue University Indianapolis

Boston University

Indiana University School of Medicine

Royal Manchester Children's Hospital

Alison Skrinar is an author at Ultragenyx Pharmaceutical (United States) specializing in medicine, pediatrics, and health sciences.

ORCID

Top concepts

Publications per year

2003–2022

34

Publications

34

A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease

Ans T. van der Ploeg, Paula R. Clemens, Deyanira Corzo et al. · New England Journal of Medicine · 2010 · 726 citations · Full text

Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia

Michael P. Whyte, Cheryl R. Greenberg, Nada Salman et al. · New England Journal of Medicine · 2012 · 554 citations · Full text

Burosumab Therapy in Children with X-Linked Hypophosphatemia

Thomas O. Carpenter, Michael P. Whyte, Erik A. Imel et al. · New England Journal of Medicine · 2018 · 449 citations · Full text

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

Erik A. Imel, Francis H. Glorieux, Michael P. Whyte et al. · The Lancet · 2019 · 347 citations · Full text

, , +2

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease

Marc Nicolino, Barry J. Byrne, J. Edmund Wraith et al. · Genetics in Medicine · 2009 · 290 citations · Full text

, , +7

Rows per page

1–5 of 34